Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Magenta Therapeutics stock | $6.53

Learn how to easily invest in Magenta Therapeutics stock.

Magenta Therapeutics Inc is a biotechnology business based in the US. Magenta Therapeutics shares (MGTA) are listed on the NASDAQ and all prices are listed in US Dollars. Magenta Therapeutics employs 78 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Magenta Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGTA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Magenta Therapeutics stock price (NASDAQ: MGTA)

Use our graph to track the performance of MGTA stocks over time.

Magenta Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$6.53
52-week range$5.89 - $14.20
50-day moving average $6.93
200-day moving average $8.99
Wall St. target price$15.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.41

Buy Magenta Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Magenta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Magenta Therapeutics price performance over time

Historical closes compared with the close of $6.53 from 2021-10-22

1 week (2021-10-18) 0.46%
1 month (2021-09-24) -12.58%
3 months (2021-07-23) -11.76%
6 months (2021-04-23) -40.09%
1 year (2020-10-23) -7.38%
2 years (2019-10-24) -30.53%
3 years (2018-10-24) 9.23
5 years (2016-10-21) N/A

Magenta Therapeutics financials

Gross profit TTM $0
Return on assets TTM -22.42%
Return on equity TTM -37.29%
Profit margin 0%
Book value $3.50
Market capitalisation $382.4 million

TTM: trailing 12 months

Shorting Magenta Therapeutics shares

There are currently 1.5 million Magenta Therapeutics shares held short by investors – that's known as Magenta Therapeutics's "short interest". This figure is 19.2% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Magenta Therapeutics shares can be evaluated.

Magenta Therapeutics's "short interest ratio" (SIR)

Magenta Therapeutics's "short interest ratio" (SIR) is the quantity of Magenta Therapeutics shares currently shorted divided by the average quantity of Magenta Therapeutics shares traded daily (recently around 264869.51219512). Magenta Therapeutics's SIR currently stands at 5.74. In other words for every 100,000 Magenta Therapeutics shares traded daily on the market, roughly 5740 shares are currently held short.

However Magenta Therapeutics's short interest can also be evaluated against the total number of Magenta Therapeutics shares, or, against the total number of tradable Magenta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Magenta Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Magenta Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0343% of the tradable shares (for every 100,000 tradable Magenta Therapeutics shares, roughly 34 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Magenta Therapeutics.

Find out more about how you can short Magenta Therapeutics stock.

Magenta Therapeutics share dividends

We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.

Magenta Therapeutics share price volatility

Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $5.89 up to $14.2. A popular way to gauge a stock's volatility is its "beta".

MGTA.US volatility(beta: 2.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 2.1507. This would suggest that Magenta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Magenta Therapeutics overview

Magenta Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent prophylaxis of graft-versus-host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc. to evaluate potential utility of MGTA-117 for conditioning of patients receiving one or more investigational lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc.

Frequently asked questions

What percentage of Magenta Therapeutics is owned by insiders or institutions?
Currently 8.23% of Magenta Therapeutics shares are held by insiders and 71.563% by institutions.
How many people work for Magenta Therapeutics?
Latest data suggests 78 work at Magenta Therapeutics.
When does the fiscal year end for Magenta Therapeutics?
Magenta Therapeutics's fiscal year ends in December.
Where is Magenta Therapeutics based?
Magenta Therapeutics's address is: 100 Technology Square, Cambridge, MA, United States, 02139
What is Magenta Therapeutics's ISIN number?
Magenta Therapeutics's international securities identification number is: US55910K1088
What is Magenta Therapeutics's CUSIP number?
Magenta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55910K108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site